1. All Products
  2. CHLOROQUINE, 155mg base, (250mg phosphate), tab.
Public Pricelist

CHLOROQUINE, 155mg base, (250mg phosphate), tab.

https://medicalguidelines.msf.org/en/node/375
https://unicat.msf.org/cat/product/11938
STD DORACHLQ3T-

Valid Article

6.5.3.1 - For curative treatment
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.5.3.2 - For chemoprevention
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
P01BA01
Anatomical Therapeutic Chemical Classification according to WHOCC
P
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

CHLOROQUINE (CQ)

Therapeutic Action

Antimalarial

Indications

nly in areas where more than 5% of malaria diagnoses are due to non-falciparum malaria and chloroquine is still effective, chloroquine can still be considered for the treatment of confirmed P. vivax or P. ovale mono-infections.

Artemisinin-based combinations (ACTs) are also effective and may have benefits over chloroquine:

  • faster parasites clearance than chloroquine;
  • simplified protocols for all forms of uncomplicated malaria;
  • long half-life allowing a longer period of suppressive post-treatment prophylaxis against relapse and reinfection;
  • effective in treating undiagnosed P. falciparum in possible mixed infections

For confirmed mixed infections (P. falciparum plus P. vivax or P. ovale), ACTs are the treatment of choice as chloroquine is not effective against P. falciparum.

Some restricted information has been hidden. Sign in to see this information

Instructions for use

WHO recommends labels and prescriptions in mg base, not in chloroquine salt (sulphate or phosphate). Non-standardised labelling of chloroquine, expressed either as salt or as base, leads to confusion, resulting in underdosing (ineffective treatment and risk of resistance) or overdosing (risk of intoxication).

  • 100 mg base is equivalent to ± 130 mg sulfate or ± 160 mg phosphate or diphosphate
  • 155 mg base is equivalent to ± 200 mg sulfate or ± 250 mg phosphate or diphosphate

(Cf Introduction: Expression of the medicines' active ingredients content)

Storage

Below 25°C ‐ Protect from sunlight